SMMT241108C30500
- 0.00
- 0.000.00%
Summit Therapeutics Newsroom
Why Summit Therapeutics Stock Was a Winner Today
Summit Therapeutics 'Unique Investment In Oncology,' Lead Drug Candidate Shows Promise Over Keytruda And Opdivo
This Tencent Music Entertainment Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
JMP Securities Initiates Summit Therapeutics(SMMT.US) With Buy Rating, Announces Target Price $32
Express News | JMP Securities Initiates Coverage On Summit Therapeutics With Market Outperform Rating, Announces Price Target of $32
Stifel Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Maintains Target Price $40
Summit Therapeutics Analyst Ratings
H.C. Wainwright Maintains Summit Therapeutics(SMMT.US) With Buy Rating, Cuts Target Price to $44
Express News | Summit Therapeutics PLC : H.c. Wainwright Cuts Target Price to $44 From $45
Decoding Summit Therapeutics Inc (SMMT): A Strategic SWOT Insight
Summit Therapeutics Inc (SMMT) Q3 2024 Earnings Call Highlights: Strategic Advances and ...
Summit Therapeutics Inc. (SMMT) Q3 2024 Earnings Call Transcript Summary
Summit Therapeutics | 10-Q: Q3 2024 Earnings Report
Summit Therapeutics Q3 Adj $(0.05) Beats $(0.07) Estimate
Express News | Summit Therapeutics Shares Down 1.4% Premarket After Q3 Results
Express News | Summit Therapeutics Reports Operational Progress and Financial Results for the Third Quarter and Nine Months Ended September 30, 2024
Express News | Summit Therapeutics Q3 Operating Income USD -58.4 Million
Summit Therapeutics 3Q Loss/Shr 8c >SMMT
Preview: Summit Therapeutics's Earnings
Express News | Reported Earlier: New Report Highlights Nuvectis Pharma's NXP900 Synergy In NSCLC And Anticipates Upcoming NXP800 Data; Positions Nuvectis Among Precision Oncology Leaders Like Nuvalent ($6.6B) And Summit Therapeutics ($15B)